Peptides Skin • Compound Evidence Profile
A research guide to NAD+ biology, redox measurements, precursor studies, and the limits of translating biomarker changes into broader conclusions.
Use this profile to separate the molecule NAD+ from related precursors and from catalog materials. It summarizes selected primary studies and points to the methods, quality documents, and focused explainers that help researchers read the evidence carefully.
Evidence and links reviewed: October 25, 2026. Selected studies from 2016–2026; this is a reading guide, not a systematic review.
What is NAD+ in cellular research?
Nicotinamide adenine dinucleotide (NAD+) is a dinucleotide cofactor found in cells. Its oxidized and reduced forms, NAD+ and NADH, participate in electron transfer and in reactions catalyzed by enzymes that consume or produce NAD-related metabolites. NAD+ is therefore a small-molecule cofactor, not a peptide.
Researchers may measure total NAD-related metabolites, the NAD+/NADH redox pair, pathway flux, or enzyme activity. Those readouts are not interchangeable: a change in one compartment or assay does not automatically describe every tissue, organelle, or physiological outcome.
The pair is interpreted in a defined sample and assay. Extraction, quenching, storage, and normalization can influence the measured ratio.
Nicotinamide riboside, nicotinamide mononucleotide, nicotinamide, and related compounds are not the same material as NAD+ itself. A precursor study must be labeled as a precursor study.
A catalog identity and lot document answer material questions. They do not reproduce the population, protocol, or clinical endpoints of a published intervention.
NAD+ pathway context and research questions
Cellular NAD+ can be supported through salvage and de novo pathways, while enzymes such as PARPs, sirtuins, and CD38 consume NAD-related substrates in different contexts. The relevant research question determines the useful measurement: abundance, redox state, turnover, compartment, or functional endpoint.
What cell and biochemical studies examine
Cell studies can test how a defined perturbation changes NAD+ pools, NADH/NAD+ balance, enzyme activity, mitochondrial readouts, or stress responses. Controls, cell type, exposure conditions, extraction workflow, and assay specificity are part of the result.
What human precursor studies can and cannot show
Human studies of nicotinamide riboside or other precursors can establish target engagement in a selected blood or tissue sample. They may also test exploratory physiological endpoints. A biomarker increase does not by itself establish a clinical benefit, and findings with a precursor should not be relabeled as direct NAD+ administration.
What analytical work adds
For a research material, identity, measured content, impurity profile, moisture, and lot traceability require documented methods. HPLC, mass spectrometry, and other assays answer different questions; one purity number is not a substitute for a complete analytical record.
What selected published studies show
Read each study as a separate research question. The table distinguishes biochemical target engagement from safety observations and from broader exploratory endpoints.
On a small screen, swipe the study table sideways.
| Study | What was studied | How to interpret it |
|---|---|---|
| Trammell et al., 2016 Nature Communications | Early human pharmacokinetic work examined how oral nicotinamide riboside affected the blood NAD metabolome and identified NAAD as a responsive biomarker. [1] | Shows biochemical target engagement for a precursor under the study conditions. It is not a clinical-outcome trial and does not characterize an NAD+ catalog lot. |
| Martens et al., 2018 Nature Communications | A randomized, double-blind, placebo-controlled crossover study in healthy middle-aged and older adults assessed chronic nicotinamide riboside supplementation and NAD-related metabolism. [2] | Supports a sustained metabolite response in the studied population, while longer-term and tissue-specific questions remain separate. |
| Dollerup et al., 2018 American Journal of Clinical Nutrition | A randomized placebo-controlled study in adults with obesity assessed nicotinamide riboside, safety, insulin-sensitivity measures, and lipid-related endpoints. [3] | Population, intervention, endpoints, and follow-up limit generalization. A safety observation is not proof of efficacy for another purpose. |
| Conze et al., 2019 Scientific Reports | An 8-week randomized, double-blind, placebo-controlled trial evaluated nicotinamide riboside chloride in healthy overweight adults, including whole-blood NAD+ and laboratory safety measures. [4] | Provides a defined short-duration human dataset. It does not establish outcomes for every age group, tissue, formulation, or route. |
| Phase-II pilot, 2026 PubMed PMID 42478598 | A 12-week randomized pilot in adults with amnestic mild cognitive impairment reported higher blood NAD+ with nicotinamide riboside but no improvement in the prespecified cognitive or total cerebral-blood-flow outcomes. [5] | Illustrates why biomarker engagement and functional outcomes should be reported separately. The pilot size and duration leave important questions open. |
Evidence limits, assay context, and documentation
Biomarker, mechanism, and outcome are different evidence levels
Mechanistic work can support a pathway hypothesis. A human biomarker result can show target engagement in the measured sample. A clinical outcome requires a suitably designed trial with a defined population, comparator, endpoint, follow-up, and analysis plan. These levels should not be collapsed into one claim.
NAD+ material identity is separate from precursor intervention evidence
Published precursor studies do not validate a separate NAD+ research material. For any lot, researchers should review the available identity, content, impurity, moisture, storage, and traceability documentation and judge whether the methods fit the intended laboratory question.
What remains uncertain
Open questions include tissue-specific NAD+ flux, compartment-specific measurement, assay harmonization, long-term safety, and whether biochemical changes translate to reproducible functional endpoints. Reviews of the field also note heterogeneous human results and limited evidence for wellness claims.
For method context, continue with the COA and HPLC checklist, how to read a COA, and purity versus measured content.
Related NAD+ and laboratory research reading
These Peptides Skin .us articles add focused context without repeating this profile.
Why NAD+ is a small-molecule cofactor and how redox context shapes interpretation.
Read the article →Is NAD+ a Peptide?Classification, terminology, and why compound identity matters in research documentation.
Read the article →MOTS-c Human ResearchA related mitochondrial research topic with a separate evidence base and different identity.
Read the article →Study Limitations and GeneralizabilityA checklist for separating a trial result from a broader claim.
Read the article →NAD+ research FAQs
Is NAD+ a peptide?
No. NAD+ is a dinucleotide cofactor and small molecule, not an amino-acid peptide. That distinction affects nomenclature, analytical methods, and how a catalog record should be described.
Do NAD+ precursor studies prove that NAD+ itself improves a health outcome?
No. A precursor intervention can change measured NAD-related metabolites, while the study’s functional outcomes may be mixed or null. The exact material, population, endpoint, and protocol must remain visible.
What does a higher blood NAD+ measurement mean?
It indicates a change in the measured sample under the study’s assay and time point. It does not automatically describe every tissue, organelle, or downstream physiological outcome.
Can a COA prove that a research material matches a clinical-trial intervention?
No. A COA can document selected lot characteristics. It cannot reproduce a trial’s formulation, manufacturing controls, population, protocol, or clinical findings.
What should researchers compare when reading an NAD+ study?
Compare compound identity, precursor or direct material, sample and assay, comparator, population, endpoint, follow-up, exclusions, funding disclosures, and the authors’ stated limitations.
Primary sources and further information
These references support the selected evidence map. Read the complete paper and methods; a citation alone is not a quality assessment.
- Trammell SAJ et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications. 2016. DOI: 10.1038/ncomms12948.
- Martens CR et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018. DOI: 10.1038/s41467-018-03421-7.
- Dollerup OL et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men. American Journal of Clinical Nutrition. 2018. DOI: 10.1093/ajcn/nqy132.
- Conze DB et al. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Scientific Reports. 2019. DOI: 10.1038/s41598-019-46120-z.
- Phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment. PubMed PMID 42478598. 2026.
- Baur JA et al. Regulation of and challenges in targeting NAD+ metabolism. Nature Reviews Molecular Cell Biology. 2024. Review of pathway assumptions, measurement, and translational limits.
